12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

IV carbamazepine regulatory update

H. Lundbeck disclosed in its 2Q13 earnings that in June FDA granted Orphan Drug designation for IV carbamazepine to...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >